FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

View source ↗

Summary

FDA approved a supplemental application for HALAVEN (eribulin mesylate) submitted by BSP Pharmaceuticals SpA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Liposarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Halaven (eribulin)

Snippet

SUPPL AP for HALAVEN (ERIBULIN MESYLATE)